A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity Disorder

Janssen Pharmaceutical K.K.253 enrolled

Overview

The main purpose of this study is to evaluate long-term safety and tolerability of JNS001 at 18 to 72 mg per day in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).

This is a multicenter, open-label (all people involved know the identity of the intervention), dose-titration (to adjust the dose of a drug until optimal result is reached), long-term safety study in adult patients with a diagnosis of ADHD. The study consists of the Long-term phase (4-week titration period and 44-week maintenance period) and the 1-week Post-study phase. The 4 week-titration period is to find the individualized dose for each patient regardless of the treatments in the preceding study (JNS001-JPN-A01). Patients will be titrated from a starting dose of 18 mg/day for 7 days, and continue with a weekly (+/- 2 days) increment of 9 or 18 mg until an individualized dose is achieved. The titration period will be followed by a 44-week maintenance period which has combined 48-week (1-year) treatment duration with the titration period. During the maintenance period, the dose will be adjusted between 18 to 72 mg depending on the patients' symptoms. In the post-study phase, safety information will be collected after the last dose of the study treatment or premature discontinuation. The study drug will be administered with water once daily in the morning at doses of 18 mg, 27 mg, 36 mg, 45 mg, 54 mg, 63 mg, or 72 mg per day. The study treatment period is 48 weeks (titration period of 4 weeks and maintenance period of 44 weeks).

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

253

Conditions

Attention-Deficit / Hyperactivity Disorder

Interventions

JNS001DRUG

18 mg, 27 mg and 36 mg tablets (18-72 mg/day) once daily for 48 weeks

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients (and their legally-acceptable representative if patients are 18 or 19 years old) must have signed an Informed Consent Form (ICF) indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study * Patients who completed the preceding study (JNS001-JPN-A01), are considered to be appropriate to continue JNS001 treatment into this extension study by investigator or subinvestigator * Women of childbearing potential must have a negative urine pregnancy test at the final assessment in the preceding study. If sexually active, continue to use an effective method of birth control throughout the study * Men must agree to use a double-barrier method of birth control and not donate sperm during the study and for 90 days after receiving the last dose of study drug. Exclusion Criteria: * Patients who have reported AEs which would prevent transfer to this study from the preceding study (JNS001-JPN-A01) * Patients who had been judged ineligible as patients for this study by investigator or subinvestigator

Locations (29)

Unnamed facility

Chiba, Japan

Unnamed facility

Chigasaki, Japan

Outcomes

Primary Outcomes

Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability

Time frame: Throughout the study period (Month 12)

Secondary Outcomes

Change in DSM-IV Total ADHD symptoms scores (18 items) of the investigator-rated CAARS-O: SV from baseline of the preceding study (JNS001-JPN-A01) to each visit and to endpoint

Time frame: Baseline to titration visits (Week 1-4) and to months 2-12 or discontinuation

Change in the scores of the CAARS-S: SV from baseline of the preceding study to each visit and to endpoint

Time frame: Baseline to months 1-12 or discontinuation

Change in the scores of the CGI-S from baseline of the preceding study in the scores of the CGI-S at each visit and endpoint

Time frame: Baseline to titration visits (Week 1-4) and to months 2-12 or discontinuation

Change in total score of Q-LES-Q-SF from baseline of the preceding study in the scores of the Q-LES-Q-SFat each visit and endpoint

Time frame: Baseline to months 1-12 or discontinuation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.